Group items matching

in title, tags, annotations or url

The leading pharmacy bodies have come together to launch the 'Save Our Pharmacies' campaign which highlights the pressure and untapped potential of the sector. Pharmacy bodies- Association of Independent Multiple Pharmacies (AIMp), Company Chemists' Association (CCA), National Pharmacy Association (NPA) and Pharmaceutical Services Negotiating Committee (PSNC) have agreed to work together on a programme of activities to lobby for fair NHS funding for pharmacies in England, including co-ordinating efforts to mobilise public support. The campaign will focus on highlighting both the pressures that pharmacies are under and the huge untapped potential of the sector - including to offer a Pharmacy First service - if appropriate resourcing is made available. Mark Lyonette, NPA Chief executive, said: "Together we will be cranking up the noise to persuade Government and NHS to make the right choices and back the community pharmacy sector with decent funding. Maintaining patient and public support is critical to our campaigning success, so this will be a key focus in the months ahead. Our joint message is very clear: pharmacies can help get the NHS back on its feet, but not while the sector itself is on its knees." The pharmacy bodies will develop shared resources for effective parliamentary lobbying and mobilising public opinion, in the face of chronic underfunding that threatens further pharmacy closures. They will also work hard to show off the value of pharmacy and to continue pushing for a fully funded Pharmacy First service.

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

The menopause is a natural aging process, whereby a woman's oestrogen level drops thus disrupting periods until they eventually stop. A woman is said to be in the menopause when her periods have stopped for 12 months. The age when this usually occurs is between 45-55 but symptoms can begin prior to this. Symptoms vary and not all women experience them all. They include hot flushes, vaginal dryness, joint and muscle pain, insomnia, reduced libido, urinary problems such as bladder weakness or Urinary Tract Infections (UTIs), but this list is not exhaustive. Up to a third of women declare that the menopause affects their quality of life. It is obvious that such physical changes can have an effect on ones well-being. Women going through the menopause are at increased risk of developing depression, low self-esteem and problems with concentration (often called brain fog). There are lots of misconceptions in the public and workplace around menopause as it is a little discussed topic. Did you know 45 per cent of women feel their menopause symptoms have had a negative impact on their work and 47 per cent of women have said that they won't tell their employer if they need to take a day-off from work because of menopausal symptoms? So, with women making up nearly half of the UKs workforce, have you thought about what support your workplace offers for you? And if you are an employer, what could you be doing to support your colleagues who need help during this time?

Businesses have a responsibility for the safety of their employees, as well as visitors that are on their premises. If an injury occurs on their property, a company can be held responsible. There are various issues and rules that may apply, so it is important to know the facts regarding such situations. Here are 4 impacts legalities to consider for your business when dealing with such incidents. STATUS OF ENVIRONMENT AND RESPONSIBILITY OF PREMISES When you are looking into injury cases that occur and involve the premises or property of a business, one of the most important aspects to consider is the status of the property itself. All property that has access to the public owned by an individual or business must be maintained in a manner that is safe for people to reasonably move around. This is often associated with sidewalks and pathways, as well as corridors, hallways, and various rooms in businesses. You must ensure that areas where people may be around are safe such as ensuring no water or substance is present on floors that would cause falls or slips, and otherwise having the signage to indicate the need for caution. This is not limited to people, but can also apply to vehicles and equipment, ensuring oil stains and spills do not endanger the operators and employees in the area. Businesses should recognize any risks that are present and also be mindful to address environmental concerns in the immediate area as they are made aware of them. If a business fails to address such potential dangers, they are indeed potentially liable for any injuries and health concerns that come as a result of willful ignorance of the situation.

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

New legislative orders approved by the Privy Council will give the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI) powers to set professional standards for Responsible Pharmacists, Superintendent Pharmacists and Chief Pharmacists. The Pharmacy (Preparation and Dispensing Errors - Hospital (and Other Pharmacy Services) Order 2022 and the Pharmacy (Responsible Pharmacists, Superintendent Pharmacists etc.) Order 2022 have been published and are expected to come into force in December 2022. Trevor Patterson, Chief Executive of the Pharmaceutical Society NI said: "We have been working with our colleagues in the GPhC and Government for some time on these two pieces of important legislation and we are delighted they have now reached the statute books. "Both Orders enable and enhance the powers we, and the GPhC, have to define the roles and responsibilities of Responsible, Superintendent and Chief Pharmacists, respectively. They also create protections against criminal prosecution for hospital pharmacists where an inadvertent error is made either in dispensing or assembly, in certain defined circumstances, similar to the protections available to colleagues working in community/registered pharmacy settings. Provisions that allow the appointment of a Deputy Registrar for our organisation will also be introduced.

The Royal Pharmaceutical Society (RPS) has appointed James Davies as Director of England. Davies will be joining RPS in January 2023 to drive professional leadership for the pharmacy profession in England, working with and for RPS members. He'll lead on national policy development, professional advocacy and member engagement across England, in partnership with the English Pharmacy Board. Davies said: "It's a privilege to take up this position within the RPS, the professional home of pharmacy. I have been a member of the RPS throughout my pharmacy career, and that has helped me to continually drive excellence in pharmacy practice. I'm excited about delivering the current RPS strategy to ensure that pharmacy is, and continues to be, at the forefront of healthcare. I'm eager to work as part of the team and with the Board, leading and developing opportunities for the profession that improve the lives of patients and the public.

The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors to start working on the quality criteria if they intend to meet the Respiratory domain of the Pharmacy Quality Scheme (PQS) 2022/23. For respiratory domain, community pharmacy contractors  must start working towards inhaler waste management; use of a spacer in patients aged 5-15 years; and personalised asthma action plans, from today (10 October). Resources are also available to support contractors with meeting the above criteria on the PQS hub page. PSNC also informed that contractors are also now able to make a claim for an Aspiration payment for the PQS 2022/23 on the NHS Business Services Authority (NHSBSA)  Manage Your Service (MYS) portal. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23.

The Council of Pharmaceutical Society NI (PSNI) has introduced an 8-week public consultation on proposed Guidance on Pharmacy Staffing Levels within registered premises. The principle-based Guidance seeks to assist Pharmacy Owners and Superintendents to ensure that each pharmacy has enough appropriately skilled and qualified staff to provide safe and effective pharmacy services to the public. All registered pharmacies will have to meet the standards set out in the Premises Standards, when commenced. PSNI said: "The proposed Guidance should also help ensure a working environment that will facilitate pharmacists to meet their professional obligations under the Professional Standards of Conduct, Ethics and Performance for Pharmacists in Northern Ireland (2016)." "Whilst other health regulators have primary responsibility for systems regulation outside of regulated premises, we consider that the principles outlined in this Guidance, will be helpful for managers working with pharmacy teams in different settings."

Former pharmacy minister Steve Brine was on Wednesday (November 2) elected chair of the influential Health and Social Care Committee, the cross-party parliamentary group that scrutinises the work of the Department of Health and Social Care and its associated public bodies. The Conservative MP for Winchester won 253 out of 432 votes beating off four other contenders for the role - Stephen Hammond, Dr Caroline Johnson, Anne Marie Morris and James Morris - in a four-stage election in which MPs voted by ranking candidates in order of preference. Dr Johnson, who was Mr Brine's main challenger, bagged 148 votes in the final round. An election for a new chair of the Health and Social Care Committee was triggered following the resignation of Jeremy Hunt MP who was appointment as chancellor of the exchequer on October 14. Issuing a statement after his election, Mr Brine said: "I welcome the opportunity as chair to continue the calm, measured work of Jeremy Hunt and to examine new solutions to support the NHS to enable it to continue providing the services that we all depend upon."

The Community Pharmacy England Committee has adopted a new approach to engagement with sector by inviting all pharmacy owners to share their views on pharmacy's finances, pressures and capacity ahead of its meeting in July. It has sought views of pharmacists via short poll by Sunday (2 July) and will have a discussion on the poll results at the meeting before reporting back to the sector afterwards. The key focus for July Committee Meeting will be to make most of £645m for the community pharmacy sector, and also on the ongoing work to make the wider case for more investment in the sector. This new way of working follows association's rebrand on 30th May which signalled the start of its new approach to engagement to help them to build stronger relationships with pharmacy owners. The association hopes this new approach will help them better engage with members and listen to pharmacy's views better.

Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire. The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters. LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee wellbeing. This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people living with skin conditions, their families and society.

The consequences of NHS workforce crisis is not limited to general practice, community pharmacies are also suffering, commented Community Pharmacy England after the General Medical Council (GMC) published a report on Friday (23 June) which warned of the burnout in the workforce. The report calls for urgent actions to break a 'vicious cycle' of unmanageable workloads, dissatisfaction and burnout that is causing UK doctors to take steps to quit. Chief Executive Janet Morrison, said: "The GMC's report is yet another clear signal of the scale of the mounting the NHS workforce crisis, and this is not limited to general practice: community pharmacies are also suffering the consequences of it." "Pharmacy teams are overstretched, feeling immense pressures, and dealing with significantly increased workloads. Pharmacy owners are also finding it impossible to make ends meet, not least given the rising staffing costs which are being driven up by workforce issues. Findings show the number of doctors who reported working beyond their rostered hours on a weekly basis rose from 59% in 2021 to 70% in 2022, and 42% said they felt unable to cope with their workload each week (up from 30% in 2021). Just half said they were satisfied in their work, down from 70% in 2021.

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

The Pharmaceutical Services Negotiating Committee on Tuesday (June 30) renamed itself as Community Pharmacy England, promising a "strengthened commitment" to champion and engage with the sector. "The name Community Pharmacy England better reflects the breadth of work that we do to both represent and support community pharmacies in England. We are their champion," the pharmacy negotiator said. Explaining that the rebranding exercise was in line with proposals put forward by the Review Steering Group (RSG), it said the rebrand was part of its Transforming Pharmacy Representation (TAPR) work and that it would signal the beginning of a "new engagement strategy" to build stronger relationships with pharmacy owners. "Becoming Community Pharmacy England is much more than a name change or a new logo, it is a driver for cultural change across our organisation. "Our members want us to be more authoritative, representative, and influential, and rebranding gives us a clearer and stronger voice, helping us to better speak out for community pharmacy."

The NHS has made major improvements across long waits, urgent and emergency services, and cancer care, latest performance figures published on Thursday (11) have shown. The number of patients waiting more than 18 months fell to 10,737 by April - down by more than 90 per cent from 124,911 in September 2021 and by more than four-fifths since the start of January when there were 54,882. Around half of NHS trusts in England have no patients on their elective care waiting lists apart from those who have chosen to wait longer. More than one in five (21%) trusts had completely eliminated 18-month waits. However, the overall waiting list has risen to over 7.3 million entries in England. "I promised I would cut NHS waiting lists and we are delivering," Prime Minister Rishi Sunak said. "Reducing 18-month waits by over 90 per cent is huge progress, and it is testament to the hard work of NHS staff who have achieved this despite one of the busiest winters on record. "We still have work to do, but backed by record government investment and the ongoing efforts of the NHS, I am confident we will get patients the care they need more quickly." Ambulance response rates have improved to their fastest in two years, with average category two response times now at 28.5 minutes and category one at 8 mins. The 62-day cancer backlog has fallen for the first time since before the pandemic, with those waiting two months or more down from 21,823 at the end of the last financial year (March 2022) to 19,248 at the end of this March (2023). This is down almost 15,000 from a peak of 34,000 in July 2022.

Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation with regards to expanded services and payment model in the pharmacy sector. Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September." CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common Conditions Service; and are in in-depth negotiations on Payment models. These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE will measure delivery and impact. NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with NICE principles and concur with Antimicrobial Stewardship policy.

The Pharmacists Defence Association (PDA) has expressed its keenness to work with the NHS nationally and at the ICB level to discuss how the pharmacist workforce can most effectively be part of the multidisciplinary team, after the publication of Long-awaited NHS England workforce plan. Welcoming its publication Alison Jones, PDA Director of Policy said: "It gives greater clarity around the future direction and strategy for professional development, training, and opportunities for those currently working in the health service or considering their future career. There is a strong emphasis on further development of the clinical role of pharmacists to support better patient care. "However, this is a plan that will take years, indeed decades to come to fruition and its success will need to be underpinned by significant funding for its entire life course. Workplace pressures, reductions in support staff, and a lack of protected learning time are matters of immediate concern for many PDA members, issues which are regularly highlighted through activities, such as the safer pharmacies survey.

Pharmacy technicians will soon be recognised as fully regulated healthcare professionals in North Ireland. Work has begun to bring pharmacy technicians under statutory regulation by the Pharmaceutical Society of Northern Ireland, health minister Robin Swann has announced. The public consultation was launched in March 2022 on a proposal to introduce statutory regulation of the Pharmacy Technician workforce in Northern Ireland. The minister said: "This will be a key enabler to enhancing the contribution that pharmacy technicians can make to the delivery of healthcare across all settings. It will allow the regulator to strengthen its role in protecting patients and promoting high standards, thereby enhancing the public's confidence and trust in pharmacy practice." He added: "While there are many practical issues to be worked through with stakeholders, and legislative change required, I have now instructed my Department's officials to develop a detailed project plan to bring about the statutory regulation of pharmacy technicians by the Pharmaceutical Society of Northern Ireland".

BioNTech and Pfizer are to start tests on humans of next-generation vaccines that protect against a wide variety of coronaviruses in the second half of the year. Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations. In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to "provide durable variant protection". The two companies are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages. The virus' persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search by companies, governments and health bodies for more reliable tools of protection. As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.